JCJun Cai

Jun Cai

*This is an algorithmically generated author record based on publicly available information.

Jun Cai has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Landmark Studies in Cell Morphology: A Bibliometric Analysis

    by Yile Lin, Chao Zhang, Huiyang Li, Haixiao Wu, Shu Li, Jun Cai, Elmar Rasimovich Musaev, Sergey Anatolyevich Ivanov, Leonid Petrovich Zhavoronkov, Chen Ding, et al.

    Introduction. Cell morphology has been a crucial area of study since the invention of the microscope, evolving significantly with the advancement of ultramicroscopic techniques. This study analyzes the top 100 most cited publications on cell morphology to uncover key research trends and influential works from the past three decades. Materials and Methods. A bibliometric analysis was conducted using the Web of Science Core Collection database, covering articles published from January 1985 to April 2023. From an initial pool of 1,251,024 articles, the top 100 most cited publications were identified. Data on publication year, citation counts, journals, authors, geographical distribution, institutions, and keywords were extracted. VOSviewer and Bibliometrix were used for statistical analysis. Results. The top 100 articles were published in 43 journals, including high-impact publications such as Nature, Science, and Cell. The most cited article, "Matrix Elasticity Directs Stem Cell Lineage Specification," had 9,832 citations. The United States contributed 70 articles. Key research themes identified included the mechanical microenvironment, stem cell research, and advanced imaging techniques. Conclusion. This study highlights the importance of the extracellular matrix and signaling pathways in determining cell morphology. It underscores the predominant role of high-impact journals and emphasizes the need for multidisciplinary approaches in future research on cell morphology.

  • Open Access

    COL11A1 Inhibits Ferroptosis in Pancreatic Cancer by Regulating AKT/Beclin 1 Dependent Autophagy

    by Hui Wang, Shuang Zhi, Zibo Yang, Na Gu, Linlin Dai, Jun Cai, Juan Wang, Dongdong Li

    Background: Collagen type XI alpha 1 (COL11A1) is overexpressed in pancreatic cancer and is often associated with poor survival, chemoresistance, and tumor recurrence. However, the role of COL11A1 in pancreatic cancer remains poorly understood. Methods: We explored the correlation between COL11A1 and overall survival in pancreatic cancer patients using Kaplan-Meier survival analysis and validated COL11A1’s regulatory role in the viability of pancreatic cancer cell line PANC-1 using Cell Counting Kit-8 and colony formation assays. To clarify the underlying mechanisms, we further examined COL11A1’s modulation of ferroptosis and autophagy in PANC-1 cells by western blot, reverse transcription quantitative polymerase chain reaction (RT-qPCR), and immunofluorescence assays. Moreover, autophagy agonist rapamycin, inhibitor 3-methyladenine (3-MA), and AKT/Beclin 1 pathway inhibitors were employed to dissect the regulatory crosstalk between COL11A1, autophagy, and ferroptosis. Results: COL11A1 expression was negatively correlated with pancreatic cancer patients’ survival rate. Its overexpression significantly enhanced the viability and clonogenic capacity of erastin- and rapamycin-treated PANC-1 cells. Our data showed that COL11A1 reduced intracellular iron levels, suppressed reactive oxygen species accumulation, downregulated malondialdehyde and microtubule—associated protein 1 light chain 3—II/I (LC3II/I) expression, while increasing glutathione (GSH), ferritin heavy chain 1 (FTH1) and solute carrier family 7 member 11 (SLC7A11) levels. Furthermore, COL11A1-mediated ferroptosis inhibition was attenuated by the autophagy agonist Rapamycin but enhanced by the inhibitor 3-MA. Notably, COL11A1 promoted AKT and Beclin 1 phosphorylation, and blocking the AKT/Beclin 1 pathway abrogated its ability to suppress autophagy and ferroptosis in pancreatic cancer cells. Conclusions: The study demonstrated that COL11A1 exerts its oncogenic effects by suppressing autophagy via the AKT/Beclin 1 pathway, consequently inhibiting ferroptosis in pancreatic cancer cells. These findings reveal a novel molecular mechanism through which COL11A1 promotes tumor progression and provide a potential therapeutic target for pancreatic cancer treatment.

  • Copper complexes suppress stemness, reverse epithelial‐to‐mesenchymal transition progression, and induce apoptosis on triple negative breast cancer

    by Dongdong Li, Linlin Dai, Luyao Wang, Cheng Tan, Jun Cai, Hui Wang, Xiumei Zhao

    Cancer stem cells (CSCs) are a small proportion of tumor cells with great tumorigenicity, self‐renewal ability, and intrinsic resistance to conventional and targeted cancer therapy; thus, targeting CSC is becoming an emerging cancer treatment. In this paper, five novel copper (II) complexes [Cu(OH‐PIP)(Tyr)(H2O)]PF6 (1), [Cu(m‐OH‐PIP)(Gly)]NO3·2.25H2O (2), [Cu(Cl‐PIP)(Gly)Br] (3), [Cu(F‐PIP)(Tyr)Cl] (4), and [Cu(F‐PIP)(Phe)Br] (5) have been synthesized and characterized by infrared spectroscopy and single crystal X‐ray diffraction analysis. All the complexes were screened for their in vitro cytotoxicity activity against a panel of human breast cancer cells (CAL‐51, MDA‐MB‐231, and MCF‐7), human liver cancer cells (HepG 2, SMMC‐7721) and human pancreatic cancer cells (PANC‐1) using MTT assay. They have potential proliferative inhibition for all the tested cancer cell lines, especially the triple‐negative breast cancer (TNBC) CAL‐51 cells are inhibited significantly with IC50 values ranging from 0.11 to 2.35 μM. Cellular functional assays showed that representative complexes 1 and 5 could trigger apoptosis, evidenced by Hoechst 33258 staining, flow cytometry assays, and the alteration of Bax, Bcl‐2, Caspase‐3, and PARP levels. In addition, they dramatically suppressed colony and mammosphere formation, inhibited cancer cell stemness and migration, and reversed epithelial–mesenchymal transition (EMT) progression in CAL‐51 cells, indicating their great potential as anti‐CSC agents for therapy of TNBC.


  • Open Access

    Lung metastases at the initial diagnosis of high-grade osteosarcoma: prevalence, risk factors and prognostic factors. A large population-based cohort study

    by Chao Zhang, Xu Guo, Yao Xu, Xiuxin Han, Jun Cai, Xin Wang, Guowen Wang

    Osteosarcoma is the most prevalent malignant bone tumor in children and adolescents. Lung metastases are associated with poor prognosis. The aim here was to explore the prevalence of and risk and prognostic factors for lung metastases in high-grade osteosarcoma patients. Retrospective cohort study based on the Surveillance, Epidemiology and End Results (SEER) database in the United States. Data on 1,408 high-grade osteosarcoma patients registered in the SEER database between 2010 and 2015 were extracted. From these, all patients with high-grade osteosarcoma and initial lung metastasis were selected for analysis on risk and prognostic factors for lung metastases. Overall survival was estimated. There were 238 patients (16.90%) with lung metastases at diagnosis. Axial location, tumor size > 10 cm (odds ratio, OR 3.19; 95% confidence interval, CI: 1.58-6.45), higher N stage (OR 4.84; 95% CI: 1.94-12.13) and presence of bone metastases (OR 8.73; 95% CI: 4.37-17.48) or brain metastases (OR 25.63; 95% CI: 1.55-422.86) were significantly associated with lung metastases. Younger age and surgical treatment (hazard ratio, HR 0.46; 95% CI: 0.30-0.71) favored survival. Median survival was prolonged through primary tumor surgery. The factors revealed here may guide lung metastasis screening and prophylactic treatment for osteosarcoma patients. A primary tumor in an axial location, greater primary tumor size, higher lymph node stage and presence of bone or brain metastases were significantly correlated with lung metastases. The elderly group (≥ 60 years) showed significant correlation with poor overall survival. For improved survival among high-grade osteosarcoma patients with lung metastases, aggressive surgery on the primary tumor site should be encouraged.